Insider Activity Highlights
On August 26, 2026, Tsuchimoto Kim R executed a sizable Rule 10b‑5‑1 purchase of 2,055 shares at $30 and a second purchase of 2,035 shares at $14, both well below the market price of $113.94. Simultaneously, the investor sold a total of 7,192 shares across seven transactions, with prices ranging from $108.83 to $113.84. The net effect was a 3,605‑share position, a modest increase from the pre‑transaction holding of 2,290 shares.
Implications for the Company and Investors
The timing of these trades—just after a surge in social‑media buzz (buzz ≈ 99.4 %) and a slight dip in the stock price—suggests that Kim R may be capitalizing on a temporary valuation distortion. The buy at $30 and $14 represents a significant discount to the current market, hinting that insiders may perceive the stock to be undervalued or that they are positioning for an upcoming catalyst such as a clinical data release or regulatory milestone. However, the substantial sell‑side activity, particularly the weighted average price of $111.84, indicates that the investor is also locking in gains as the share price approaches its 52‑week high of $124.82. For investors, this dual pattern is a warning sign: while insiders may still hold a long‑term view, they are also actively managing risk and harvesting profits.
Tsuchimoto Kim R – A Transaction Profile
Kim R’s historic filing history shows a preference for Rule 10b‑5‑1 plans and a pattern of buying at deep discounts followed by staged selling as the price climbs. The most recent batch of sales on August 26, 2026, is the largest cluster of trades by this insider, underscoring a disciplined, plan‑driven approach. The investor’s overall holding of roughly 2,290 shares—about 0.01 % of outstanding shares—suggests a modest stake, yet the concentrated trades indicate an active management strategy rather than passive ownership.
What This Means for the Future
Monopar Therapeutics is a mid‑cap biopharma with a growing pipeline aimed at improving cancer outcomes. The insider activity reflects a mix of optimism and prudence: buying at attractive prices while taking profits as the stock rallies. For the broader market, the insider activity adds a layer of complexity to the stock’s recent rally, potentially tempering expectations for further upside until a clear corporate event—such as a product approval or partnership—materializes. Investors should monitor subsequent 10‑4 filings for additional clues about insider confidence and watch the company’s quarterly earnings for any catalyst that could justify the current valuation.
Key Takeaways
- Insider buys at $30 and $14 are stark discounts to today’s $113.94 market price, suggesting potential undervaluation.
- Aggressive sell‑side trades at $110–$113.84 indicate profit‑taking as the stock approaches its 52‑week peak.
- Kim R’s pattern of plan‑based trades reflects a disciplined, risk‑managed approach, not a speculative gamble.
- For investors, the insider behavior signals both optimism for a future catalyst and caution against over‑valuation in the interim.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026-08-26 | Tsuchimoto Kim R () | Buy | 2,055.00 | 30.00 | Common Stock |
| 2026-08-26 | Tsuchimoto Kim R () | Buy | 2,035.00 | 14.00 | Common Stock |
| 2026-08-26 | Tsuchimoto Kim R () | Sell | 485.00 | 108.83 | Common Stock |
| 2026-08-26 | Tsuchimoto Kim R () | Sell | 615.00 | 109.56 | Common Stock |
| 2026-08-26 | Tsuchimoto Kim R () | Sell | 700.00 | 110.65 | Common Stock |
| 2026-08-26 | Tsuchimoto Kim R () | Sell | 1,098.00 | 111.84 | Common Stock |
| 2026-08-26 | Tsuchimoto Kim R () | Sell | 602.00 | 112.93 | Common Stock |
| 2026-08-26 | Tsuchimoto Kim R () | Sell | 590.00 | 113.84 | Common Stock |
| N/A | Tsuchimoto Kim R () | Holding | 11,486.00 | N/A | Common Stock |
| 2026-08-26 | Tsuchimoto Kim R () | Buy | 2,055.00 | N/A | Stock Option |
| 2026-08-26 | Tsuchimoto Kim R () | Buy | 2,035.00 | N/A | Stock Option |
